Anavex Life Sciences Corp. Income Statement

Income Statement Sep2013 Sep2014 Sep2015 Sep2016 Sep2017 Sep2018 Sep2019 Sep2020 Sep2021 Sep2022 Sep2023 Sep2024 Sep2025
Operating items
Research & Development 2.27M7.25M10.67M13.34M22.26M25.23M32.98M37.92M43.72M41.84M
Selling, General & Administrative 4.84M8.33M5.01M5.99M6.85M5.86M9.02M13.07M12.04M11.04M
Other Operating Expenses -62.18M
Operating Expenses 7.11M15.59M15.68M19.33M29.11M-31.09M42.00M50.99M55.76M52.88M
Operating Income -31.09M-42.00M-50.99M-55.76M-52.88M
EBIT -12.11M-14.71M-13.40M-17.18M-26.21M-31.09M-42.00M-50.99M-55.76M-52.88M
Non-operating items
Other Non Operating Income 0.07M-0.05M-0.05M-0.05M0.12M0.13M-0.27M-0.90M-0.04M0.19M
Non Operating Income -5.00M0.88M2.28M2.15M2.89M4.83M4.36M3.37M8.26M9.88M
Net income details
EBT -12.11M-14.71M-13.40M-17.18M-26.21M-26.26M-37.64M-47.62M-47.50M-43.00M
Tax Provisions 0.03M0.06M0.07M0.08M0.02M0.27M0.36M0.01M
Profit After Tax -12.11M-14.74M-13.46M-17.25M-26.29M-26.28M-37.91M-47.98M-47.51M-43.00M
Income from Continuing Operations -12.11M-14.74M-13.46M-17.25M-26.29M-26.28M-37.91M-47.98M-47.51M-43.00M
Consolidated Net Income -12.11M-14.74M-13.46M-17.25M-26.29M-26.28M-37.91M-47.98M-47.51M-43.00M
Income towards Parent Company -12.11M-14.74M-13.46M-17.25M-26.29M-26.28M-37.91M-47.98M-47.51M-43.00M
Net Income towards Common Stockholders -12.11M-14.74M-13.46M-17.25M-26.29M-26.28M-37.91M-47.98M-47.51M-43.00M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M
Shares Outstanding (Weighted Average) 9.31M9.57M34.60M39.61M42.17M45.43M52.65M60.19M75.71M77.94M81.95M84.80M85.89M
EBITDA -12.11M-14.71M-13.40M-17.18M-26.21M-31.09M-42.00M-50.99M-55.76M-52.88M